ArticleAnnals of laboratory medicine2013
Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer.
Article in Annals of laboratory medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 6 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Pooled it
- Pooled it
- Quantitative assessment of the association between APC promoter methylation and breast cancer.Oncotarget · 2016Pooled it
- Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.Scientific reports · 2015Pooled it
- Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies.BMC cancer · 2015Pooled it
- Pooled it
- Hypermethylation of the BRCA2 gene promoter and its co-hypermethylation with the BRCA1 gene promoter in patients with breast cancer.Cancer biomarkers : section A of Disease markers · 2024Article
- Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer.Breast cancer research and treatment · 2022Article
- Epigenetic alterations in canine mammary cancer.Genetics and molecular biology · 2022Article
- The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis.Cancers · 2021Review
- Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast CancerAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.Breast cancer : basic and clinical research · 2016Review
- Article
- Epigenetic markers in melanoma.Melanoma management · 2015Review
- Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation.BMC cancer · 2015Article
- Genetic risk variants associated with in situ breast cancer.Breast cancer research : BCR · 2015Article
- Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients.SpringerPlus · 2015Article
- The functional role of long non-coding RNAs and epigenetics.Biological procedures online · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAberrant DNA hypermethylation plays a pivotal role in carcinogenesis and disease progression; therefore, accurate measurement of differential gene methylation patterns among many genes is likely to reveal biomarkers for improved risk assessment. We evaluated the gene hypermethylation profiles of primary breast tumors and their corresponding normal tissues and investigated the association between major clinicopathological features and gene hypermethylation.
methodsA single reaction using methylation-specific multiplex ligation-dependent probe amplification was used to analyze the DNA methylation status of 24 tumor suppressor genes in 60 cancerous tissues and their corresponding normal tissues from patients with primary breast cancer.
resultsIn cancerous breast tissues, 21 of 24 genes displayed promoter methylation in one or more samples. The most frequently methylated genes included RASSF1 (43.3%), APC (31.7%), CDKN2B (25.0%), CDH13 (23.3%), GSTP1 (16.7%), and BRCA1 (10%). APC was associated with lymph node metastasis, and BRCA1 was associated with negative estrogen receptor and negative progesterone receptor expression. In normal breast tissues, 8 of 24 tumor suppressor genes displayed promoter hypermethylation; CDKN2B (28.3%) and RASSF1 (8.3%) hypermethylation were most frequently observed.
conclusionsRASSF1 and CDKN2B hypermethylation in Korean breast cancer patients were the most frequent in cancerous tissue and corresponding normal tissue, respectively. Our data indicates that methylation of specific genes is a frequent event in morphologically normal breast tissues adjacent to breast tumors as well as the corresponding breast cancers. This study also suggests that gene methylation is linked to various pathological features of breast cancer; however, this requires confirmation in a larger study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.